Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
NPD's Cash to Debt is ranked higher than
97% of the 368 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.53 vs. NPD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NPD' s Cash to Debt Range Over the Past 10 Years
Min: 2.27  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.53
NPD's Equity to Asset is ranked higher than
69% of the 367 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.43 vs. NPD: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
NPD' s Equity to Asset Range Over the Past 10 Years
Min: 0  Med: 0.63 Max: 0.87
Current: 0.53
0
0.87
Interest Coverage No Debt
NPD's Interest Coverage is ranked higher than
97% of the 306 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.62 vs. NPD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NPD' s Interest Coverage Range Over the Past 10 Years
Min: 17.73  Med: 10000.00 Max: 9999.99
Current: No Debt
17.73
9999.99
F-Score: 5
Z-Score: 4.13
WACC vs ROIC
11.64%
7.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 2.28
NPD's Operating margin (%) is ranked lower than
57% of the 369 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 2.91 vs. NPD: 2.28 )
Ranked among companies with meaningful Operating margin (%) only.
NPD' s Operating margin (%) Range Over the Past 10 Years
Min: -0.1  Med: 1.75 Max: 9.25
Current: 2.28
-0.1
9.25
Net-margin (%) 1.53
NPD's Net-margin (%) is ranked lower than
52% of the 370 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.70 vs. NPD: 1.53 )
Ranked among companies with meaningful Net-margin (%) only.
NPD' s Net-margin (%) Range Over the Past 10 Years
Min: -0.47  Med: 1.34 Max: 8.04
Current: 1.53
-0.47
8.04
ROE (%) 5.91
NPD's ROE (%) is ranked lower than
60% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 8.52 vs. NPD: 5.91 )
Ranked among companies with meaningful ROE (%) only.
NPD' s ROE (%) Range Over the Past 10 Years
Min: -1.63  Med: 4.58 Max: 9.01
Current: 5.91
-1.63
9.01
ROA (%) 3.17
NPD's ROA (%) is ranked higher than
50% of the 371 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 3.30 vs. NPD: 3.17 )
Ranked among companies with meaningful ROA (%) only.
NPD' s ROA (%) Range Over the Past 10 Years
Min: -0.84  Med: 2.39 Max: 7.3
Current: 3.17
-0.84
7.3
ROC (Joel Greenblatt) (%) 16.82
NPD's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 369 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 15.13 vs. NPD: 16.82 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NPD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -0.63  Med: 22.48 Max: 122.76
Current: 16.82
-0.63
122.76
Revenue Growth (3Y)(%) 7.30
NPD's Revenue Growth (3Y)(%) is ranked higher than
68% of the 324 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.00 vs. NPD: 7.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NPD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.4  Med: 7.80 Max: 58.5
Current: 7.3
-11.4
58.5
EBITDA Growth (3Y)(%) -17.70
NPD's EBITDA Growth (3Y)(%) is ranked lower than
89% of the 293 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.30 vs. NPD: -17.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NPD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -17.70 Max: 120.1
Current: -17.7
0
120.1
EPS Growth (3Y)(%) -24.50
NPD's EPS Growth (3Y)(%) is ranked lower than
91% of the 255 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 4.60 vs. NPD: -24.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NPD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -52.3  Med: -30.15 Max: -5.8
Current: -24.5
-52.3
-5.8
» NPD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-09-02)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

NPD Guru Trades in Q2 2015

Jim Simons 731,400 sh (+12.26%)
» More
Q3 2015

NPD Guru Trades in Q3 2015

Jim Simons 763,800 sh (+4.43%)
» More
Q4 2015

NPD Guru Trades in Q4 2015

Jim Simons 792,400 sh (+3.74%)
» More
Q1 2016

NPD Guru Trades in Q1 2016

Jim Simons 822,100 sh (+3.75%)
» More
» Details

Insider Trades

Latest Guru Trades with NPD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Retail - Defensive » Pharmaceutical Retailers
Compare:OTCPK:CRPNF, OTCBB:COCP, NAS:PETS, NAS:CJJD, OTCPK:HEWA, OTCPK:CLIGF, NYSE:GNC, OTCPK:CLCGY, OTCPK:JCOUF, OTCPK:SDGCF, NYSE:RAD, NAS:WBA » details
Traded in other countries:4CSA.Germany,
China Nepstar Chain Drugstore Ltd are engaged in the business of operating retail drugstores in the People's Republic of China. It provide pharmacy services and other merchandise, including over-the-counter drugs, and nutritional supplements.

China Nepstar Chain Drugstore Ltd was incorporated in the Cayman Islands in August 2004. The Company operates retail drugstore business. The Company provides professional and convenient pharmacy services and other merchandise, including over-the-counter drugs, nutritional supplements, herbal products, personal care products, family care products, as well as convenience products including consumable, seasonal and promotional items. It also offers private label products. The Company offers 523 nutritional supplements, including a variety of healthcare supplements, vitamins, minerals and dietary products. Its other products include personal care products such as skin care, hair care and beauty products, family care products such as portable medical devices for family use, birth control and early pregnancy test products, and convenience products, including soft drinks, packaged snacks, cleaning agents and stationery. The other products also include seasonal and promotional items tailored to local consumer demand for convenience and quality. The Company also provides ancillary services such as providing free blood pressure measurements in its stores. The Company competes with other retail drugstore chains or independent drugstores. As a distributor and retailer of pharmaceutical products, the Company is subject to regulation and oversight by different levels of the food and drug administration in China, in particular, the State Food and Drug Administration, or the SFDA.

Ratios

vs
industry
vs
history
P/E(ttm) 30.50
NPD's P/E(ttm) is ranked lower than
74% of the 300 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.81 vs. NPD: 30.50 )
Ranked among companies with meaningful P/E(ttm) only.
NPD' s P/E(ttm) Range Over the Past 10 Years
Min: 10.55  Med: 38.83 Max: 1914.24
Current: 30.5
10.55
1914.24
PE(NRI) 30.50
NPD's PE(NRI) is ranked lower than
75% of the 299 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.67 vs. NPD: 30.50 )
Ranked among companies with meaningful PE(NRI) only.
NPD' s PE(NRI) Range Over the Past 10 Years
Min: 10.55  Med: 38.04 Max: 971.76
Current: 30.5
10.55
971.76
P/B 1.76
NPD's P/B is ranked lower than
52% of the 361 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.67 vs. NPD: 1.76 )
Ranked among companies with meaningful P/B only.
NPD' s P/B Range Over the Past 10 Years
Min: 0.69  Med: 1.49 Max: 4.86
Current: 1.76
0.69
4.86
P/S 0.47
NPD's P/S is ranked lower than
51% of the 364 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.45 vs. NPD: 0.47 )
Ranked among companies with meaningful P/S only.
NPD' s P/S Range Over the Past 10 Years
Min: 0.28  Med: 0.61 Max: 5.83
Current: 0.47
0.28
5.83
EV-to-EBIT 15.26
NPD's EV-to-EBIT is ranked lower than
53% of the 305 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 14.53 vs. NPD: 15.26 )
Ranked among companies with meaningful EV-to-EBIT only.
NPD' s EV-to-EBIT Range Over the Past 10 Years
Min: -249.1  Med: 15.40 Max: 64
Current: 15.26
-249.1
64
EV-to-EBITDA 15.26
NPD's EV-to-EBITDA is ranked lower than
70% of the 313 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 10.56 vs. NPD: 15.26 )
Ranked among companies with meaningful EV-to-EBITDA only.
NPD' s EV-to-EBITDA Range Over the Past 10 Years
Min: -249.1  Med: 15.40 Max: 64
Current: 15.26
-249.1
64
Shiller P/E 24.78
NPD's Shiller P/E is ranked lower than
59% of the 79 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 20.50 vs. NPD: 24.78 )
Ranked among companies with meaningful Shiller P/E only.
NPD' s Shiller P/E Range Over the Past 10 Years
Min: 17.13  Med: 24.40 Max: 39.75
Current: 24.78
17.13
39.75
Current Ratio 1.92
NPD's Current Ratio is ranked higher than
78% of the 353 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.19 vs. NPD: 1.92 )
Ranked among companies with meaningful Current Ratio only.
NPD' s Current Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.50 Max: 6.94
Current: 1.92
1.17
6.94
Quick Ratio 1.07
NPD's Quick Ratio is ranked higher than
73% of the 353 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 0.72 vs. NPD: 1.07 )
Ranked among companies with meaningful Quick Ratio only.
NPD' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 1.70 Max: 6.33
Current: 1.07
0.49
6.33
Days Inventory 110.55
NPD's Days Inventory is ranked lower than
92% of the 356 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 39.94 vs. NPD: 110.55 )
Ranked among companies with meaningful Days Inventory only.
NPD' s Days Inventory Range Over the Past 10 Years
Min: 79.13  Med: 117.94 Max: 122.17
Current: 110.55
79.13
122.17
Days Sales Outstanding 19.39
NPD's Days Sales Outstanding is ranked lower than
58% of the 289 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 13.62 vs. NPD: 19.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
NPD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.46  Med: 14.25 Max: 17.85
Current: 19.39
8.46
17.85
Days Payable 96.04
NPD's Days Payable is ranked higher than
85% of the 293 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 45.66 vs. NPD: 96.04 )
Ranked among companies with meaningful Days Payable only.
NPD' s Days Payable Range Over the Past 10 Years
Min: 77.56  Med: 92.11 Max: 100.17
Current: 96.04
77.56
100.17

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 2.77
NPD's Price/Net Current Asset Value is ranked higher than
72% of the 125 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 6.00 vs. NPD: 2.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
NPD' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.09  Med: 2.06 Max: 5.07
Current: 2.77
1.09
5.07
Price/Tangible Book 1.91
NPD's Price/Tangible Book is ranked higher than
50% of the 321 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.90 vs. NPD: 1.91 )
Ranked among companies with meaningful Price/Tangible Book only.
NPD' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.75  Med: 1.54 Max: 4.67
Current: 1.91
0.75
4.67
Price/Projected FCF 2.30
NPD's Price/Projected FCF is ranked lower than
99.99% of the 219 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.42 vs. NPD: 2.30 )
Ranked among companies with meaningful Price/Projected FCF only.
NPD' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.12  Med: 1.73 Max: 12.77
Current: 2.3
1.12
12.77
Price/Median PS Value 0.76
NPD's Price/Median PS Value is ranked higher than
80% of the 337 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.04 vs. NPD: 0.76 )
Ranked among companies with meaningful Price/Median PS Value only.
NPD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.54  Med: 0.97 Max: 9.16
Current: 0.76
0.54
9.16
Price/Graham Number 1.59
NPD's Price/Graham Number is ranked lower than
54% of the 253 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 1.49 vs. NPD: 1.59 )
Ranked among companies with meaningful Price/Graham Number only.
NPD' s Price/Graham Number Range Over the Past 10 Years
Min: 0.67  Med: 1.63 Max: 5.83
Current: 1.59
0.67
5.83
Earnings Yield (Greenblatt) (%) 6.63
NPD's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 366 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 5.90 vs. NPD: 6.63 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
NPD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 1.6  Med: 5.60 Max: 162.7
Current: 6.63
1.6
162.7
Forward Rate of Return (Yacktman) (%) -36.36
NPD's Forward Rate of Return (Yacktman) (%) is ranked lower than
99% of the 226 Companies
in the Global Pharmaceutical Retailers industry.

( Industry Median: 7.18 vs. NPD: -36.36 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
NPD' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -36.4  Med: -26.60 Max: 42.2
Current: -36.36
-36.4
42.2

More Statistics

Revenue (TTM) (Mil) $518.1
EPS (TTM) $ 0.08
Beta1.32
Short Percentage of Float0.13%
52-Week Range $1.75 - 2.69
Shares Outstanding (Mil)98.70
» More Articles for NPD

Headlines

Articles On GuruFocus.com
High Yield George Soros Stocks: China Nepstar ADS, Chimera Investment, PDL BioPharma, MFA Mortgage I Apr 22 2010 
Ron Baron Likes Layne Christensen, Ritchie Brothers Auctioneers, Bankrate and China Nepstar Mar 25 2008 

More From Other Websites
China Nepstar Chain Drugstore Ltd. :NPD-US: Earnings Analysis: Q1, 2016 By the Numbers : June 22,... Jun 22 2016
China Nepstar Chain Drugstore Ltd. Announces Extraordinary General Meeting of Shareholders Jun 22 2016
China Nepstar Chain Drugstore Ltd. Announces Extraordinary General Meeting of Shareholders Jun 22 2016
China Nepstar Chain Drugstore Ltd Earnings Call scheduled for 8:00 am ET today May 31 2016
Q1 2016 China Nepstar Chain Drugstore Ltd Earnings Release - Before Market Open May 31 2016
China Nepstar Chain Drugstore Ltd. Reports First Quarter 2016 Financial Results May 31 2016
China Nepstar Chain Drugstore Ltd. Reports First Quarter 2016 Financial Results May 31 2016
Investor Calendar Invites You to the China Nepstar Chain Drugstore First Quarter 2016 Earnings... May 27 2016
China Nepstar Chain Drugstore to Report First Quarter 2016 Financial Results on May 31, 2016 May 25 2016
China Nepstar Chain Drugstore to Report First Quarter 2016 Financial Results on May 31, 2016 May 25 2016
CHINA NEPSTAR CHAIN DRUGSTORE LTD. Financials Apr 29 2016
China Nepstar Chain Drugstore Filed 2015 Annual Report on Form 20-F Apr 27 2016
China Nepstar Chain Drugstore Filed 2015 Annual Report on Form 20-F Apr 27 2016
China Nepstar Chain Drugstore Ltd. :NPD-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 31 2016
China Nepstar Chain Drugstore Ltd. :NPD-US: Earnings Analysis: 2015 By the Numbers Mar 31 2016
China Nepstar Chain Drugstore Ltd Earnings Call scheduled for 8:00 am ET today Mar 29 2016
China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2015 Financial Results Mar 29 2016
China Nepstar Chain Drugstore Ltd. Reports Fourth Quarter and Fiscal Year 2015 Financial Results Mar 29 2016
Investor Calendar Invites You to the China Nepstar Chain Drugstore Fourth Quarter and Fiscal Year... Mar 28 2016
China Nepstar Chain Drugstore Ltd. Enters into Definitive Merger Agreement for Going Private... Mar 16 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)